Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 70, Issue 2, 2004, Pages 99-100

  Paladini, Dario ^a,b   Vassallo, Michele ^b   D'Armiento, Maria Rosaria ^b   Cianciaruso, Bruno ^b   Martinelli, Pasquale ^a  

^a University Federico II of Naples ^*

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyclophosphamide; Human fetus; Prenatal diagnosis; Teratogenesis; Ultrasound

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECHOGRAPHY; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; IMAGE ANALYSIS; KARYOTYPE; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; NAGER ACROFACIAL DYSOSTOSIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS;

EID: 1542306677     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.10147     Document Type: Letter

References (8)

1. Enns GM, Roeder E, Chan RT, et al. 1999. Apparent cyclophosphamide embryopathy: a distinct phenotype? Am J Med Genet 86:237-241.
2. Kirshon B, Wasserstrum N, Willis R, et al. 1988. Teratogenic effect of first trimester cyclophosphamide therapy. Obstet Gynecol 72:462-464.
3. Jones LK. 1997. Smith's recognizable patterns of human malformation. 5th edition. Philadelphia: WB Saunders Company. p 14-17.
4. Paladini D, Tartaglione A, Lamberti A, et al. 2003. Prenatal ultrasound diagnosis of Nager syndrome, Ultrasound Obstet Gynecol 21:195-197.
5. Park-Wyllie L, Mazzetta P, Pasturszak P, et al. 2000. Birth defects after maternal exposure to corticosteroids.: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385-392.
6. Pavlidis NA. 2002. Coexistence of pregnancy and malignancy. Oncologist 7:279-287.
7. Porter AJ, Singh SM. 1988. Transplacental teratogenesis and mutagenesis in mouse fetuses treated with cyclophosphamide. Teratog Carcinog Mutagen 8:191-203.
8. Vaux KK, Kahole NCO, Jones KL. 2003. Cyclophosphamide, methotrexate and cytarabine embryopathy: is apoptosis the common pathway? Birth Defects Res Part A Clin Mol Teratol 67A:403-408.